Cellular and molecular targets of extracellular vesicles from mesenchymal stem-stromal cells in rheumatoid arthritis

dc.centroUniversidad Cardenal Herrera-CEU
dc.contributor.authorAlcaraz Tormo, María José
dc.contributor.authorGuillén Salazar, Isabel
dc.contributor.otherProducción Científica UCH 2022
dc.contributor.otherUCH. Departamento de Farmacia
dc.date2022
dc.date.accessioned2023-06-16T04:00:18Z
dc.date.available2023-06-16T04:00:18Z
dc.date.issued2022-12-16
dc.descriptionEste artículo se encuentra disponible en la siguiente URL: https://academic.oup.com/stcltm/article/11/12/1177/6786226
dc.description.abstractRheumatoid arthritis (RA) is a chronic autoimmune disease that causes progressive joint destruction. Despite the advances in the treatment of this condition there remains a clinical need for safe therapies leading to clinical remission. Mesenchymal stem/stromal cells (MSCs) play immunomodulatory and regenerative roles which can be partly mediated by their secretome. In recent years, the important contribution of extracellular vesicles (EVs) to MSC actions has received an increasing interest as a new therapeutic approach. We provide an extensive overview of the immunomodulatory properties of MSC EVs and their effects on articular cells such as fibroblast-like synoviocytes that play a central role in joint destruction. This review discusses the anti-arthritic effects of MSC EVs in vitro and in animal models of RA as well as their potential mechanisms. Recent preclinical data suggest that transfer of non-coding RNAs by MSC EVs regulates key signaling pathways involved in the pathogenesis of RA. We also examine a number of EV modifications for improving their anti-arthritic efficacy and carrier ability for drug delivery.
dc.formatapplication/pdf
dc.identifier.citationAlcaraz, M. J. & Guillén, M. I. (2022). Cellular and molecular targets of extracellular vesicles from mesenchymal stem/stromal cells in rheumatoid arthritis. Stem Cells Translational Medicine, vol. 11, i. 12 (dec.), pp. 1177–1185. DOI: https://doi.org/10.1093/stcltm/szac075
dc.identifier.doihttps://doi.org/10.1093/stcltm/szac075
dc.identifier.issn2157-6564
dc.identifier.issn2157-6580 (Electrónico)
dc.identifier.urihttp://hdl.handle.net/10637/14443
dc.languagees
dc.language.isoen
dc.publisherOxford University
dc.relationEste artículo de investigación ha sido financiado por una beca del Ministerio de Ciencia, Innovación y Universidades del Gobierno de España y el FEDER (SAF2017-85806-R).
dc.relationUCH. Financiación Nacional
dc.relation.ispartofStem Cells Translational Medicine, vol. 11, i. 12 (dec. 2022)
dc.relation.projectIDSAF2017-85806-R
dc.rightsopen access
dc.rights.cchttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subjectRheumatoid arthritis - Treatment.
dc.subjectCélulas madre - Uso terapéutico.
dc.subjectArtritis reumatoide - Tratamiento.
dc.subjectEnfermedades autoinmunes - Tratamiento.
dc.subjectAutoimmune diseases - Treatment.
dc.subjectStem cells - Therapeutic use.
dc.titleCellular and molecular targets of extracellular vesicles from mesenchymal stem-stromal cells in rheumatoid arthritis
dc.typeArtículo
dspace.entity.typePublicationes
relation.isAuthorOfPublicationc4376958-fc57-4066-a49d-6bbcadd31085
relation.isAuthorOfPublication.latestForDiscoveryc4376958-fc57-4066-a49d-6bbcadd31085

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Cellular_Alcaraz_SCTM_2022.pdf
Size:
4.9 MB
Format:
Adobe Portable Document Format

Collections